Amphastar P (AMPH)vsJohnson & Johnson (JNJ)
AMPH
Amphastar P
$29.37
+1.73%
HEALTHCARE · Cap: $1.22B
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 13219% more annual revenue ($99.33B vs $745.79M). JNJ leads profitability with a 16.2% profit margin vs 13.3%. AMPH appears more attractively valued with a PEG of 2.77. AMPH earns a higher WallStSmart Score of 65/100 (C+).
AMPH
Buy65
out of 100
Grade: C+
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.3%
Fair Value
$39.87
Current Price
$29.37
$10.50 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 135.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : AMPH
The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
AMPH profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
AMPH carries more volatility with a beta of 0.94 — expect wider price swings.
AMPH is growing revenue faster at 8.2% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
AMPH scores higher overall (65/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?